
Johnny Vercouillie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5972486/publications.pdf Version: 2024-02-01



JOHNNY VERCOULLIE

#	Article	IF	CITATIONS
1	Imaging of dopamine transporter with [18F]LBT-999: initial evaluation in healthy volunteers. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, .	0.7	5
2	Synthesis of γ-carboline N-oxide under gold(I)-catalysis and C-1 amino and fluoro γ-carboline. Tetrahedron, 2021, , 132154.	1.9	1
3	[¹⁸ F]â€labeled positron emission tomography ligand for the histamine H4 receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 363-372.	1.0	0
4	Study of influence of the glutamatergic concentration of [18F]FPEB binding to metabotropic glutamate receptor subtype 5 with N-acetylcysteine challenge in rats and SRM/PET study in human healthy volunteers. Translational Psychiatry, 2021, 11, 66.	4.8	6
5	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. Theranostics, 2021, 11, 6644-6667.	10.0	42
6	Longitudinal PET Imaging of α7 Nicotinic Acetylcholine Receptors with [18F]ASEM in a Rat Model of Parkinson's Disease. Molecular Imaging and Biology, 2020, 22, 348-357.	2.6	11
7	Usefulness of PET With [18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment. Frontiers in Neurology, 2020, 11, 754.	2.4	6
8	Training the next generation of radiopharmaceutical scientists. Nuclear Medicine and Biology, 2020, 88-89, 10-13.	0.6	7
9	Fully automated radiosynthesis of [18F]LBT999 on TRACERIab FXFN and AllinOne modules, a PET radiopharmaceutical for imaging the dopamine transporter in human brain. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 26.	3.9	2
10	Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [18F]-radiolabeling and PET study in rats. European Journal of Medicinal Chemistry, 2019, 179, 449-469.	5.5	4
11	The Story of the Dopamine Transporter PET Tracer LBT-999: From Conception to Clinical Use. Frontiers in Medicine, 2019, 6, 90.	2.6	13
12	Design of selective COX-2 inhibitors in the (aza)indazole series. Chemistry, <i>in vitro</i> studies, radiochemistry and evaluations in rats of a [¹⁸ F] PET tracer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1-7.	5.2	24
13	Extensive exploration of a novel rat model of Parkinson's disease using partial 6â€hydroxydopamine lesion of dopaminergic neurons suggests newÂtherapeutic approaches. Synapse, 2019, 73, e22077.	1.2	11
14	Amyloid PET Positivity in Different Primary Progressive Aphasia Phenotypes. Clinical Nuclear Medicine, 2018, 43, e103-e108.	1.3	3
15	Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state. Theranostics, 2018, 8, 5400-5418.	10.0	48
16	Abstract 1875A: Preclinical proof of concept for the first Nanocyclix TKI-PET radiotracer targeting activated EGFR positive lung tumors. , 2017, , .		4
17	Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [18F]DPA-714 PET Imaging. Molecular Imaging, 2016, 15, 153601211663918.	1.4	15
18	Tandem Silverâ€Catalyzed Cyclization/Nucleophilic Functionalization of 2â€Alkynylindoleâ€3â€carbaldehyde Oximes to Afford New 2,4â€Disubstituted γâ€Carbolines. European Journal of Organic Chemistry, 2016, 2016, 5024-5036.	2.4	9

JOHNNY VERCOUILLIE

#	Article	IF	CITATIONS
19	Guidelines to PET measurements of the target occupancy in the brain for drug development. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2255-2262.	6.4	28
20	Radiopharmaceuticals for PET imaging of neuroinflammation. Medecine Nucleaire, 2016, 40, 72-81.	0.2	5
21	Design of α7 nicotinic acetylcholine receptor ligands using the (het)Aryl-1,2,3-triazole core: Synthesis, inÂvitro evaluation and SAR studies. European Journal of Medicinal Chemistry, 2016, 107, 153-164.	5.5	11
22	Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [18F]LBT-999 in a Parkinson's Disease Rat Model. Frontiers in Medicine, 2015, 2, 61.	2.6	25
23	Precuneus and Cingulate Cortex Atrophy and Hypometabolism in Patients with Alzheimer's Disease and Mild Cognitive Impairment: MRI and ¹⁸ F-FDG PET Quantitative Analysis Using FreeSurfer. BioMed Research International, 2015, 2015, 1-8.	1.9	90
24	Amyloid load and translocator protein 18ÂkDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiology of Aging, 2015, 36, 1639-1652.	3.1	43
25	18F-FDG and 18F-Florbetapir PET in Clinical Practice. Clinical Nuclear Medicine, 2015, 40, e111-e116.	1.3	17
26	PET tracers for imaging brain α7 nicotinic receptors: an update. Chemical Communications, 2015, 51, 14826-14831.	4.1	12
27	Design of α7 nicotinic acetylcholine receptor ligands in quinuclidine, tropane and quinazoline series. Chemistry, molecular modeling, radiochemistry, inÂvitro and in rats evaluations of a [18F] quinuclidine derivative. European Journal of Medicinal Chemistry, 2014, 82, 214-224.	5.5	18
28	In vivo PET quantification of the dopamine transporter in rat brain with [18F]LBT-999. Nuclear Medicine and Biology, 2014, 41, 106-113.	0.6	14
29	Sulfur–Carbon Bond Formation through Ringâ€Opening of Triazolothiadiazole with Organometallics. European Journal of Organic Chemistry, 2014, 2014, 3225-3231.	2.4	10
30	EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD). European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2175-2185.	6.4	31
31	Could 18 F-DPA-714 PET imaging be interesting to use in the early post-stroke period?. EJNMMI Research, 2014, 4, 28.	2.5	40
32	The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using 18F-AV45: Is Amyloid the Principal Actor in the Disease. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 431-441.	1.3	10
33	Distribution physiologique cérébrale et corps entier du 18F-DPA-714Âen TEP/TDM. Medecine Nucleaire, 2013, 37, 44-51.	0.2	0
34	Aromatic fluoro-de-triazenation with boron trifluoride diethyl etherate under non-protic acid conditions. Journal of Fluorine Chemistry, 2013, 147, 5-9.	1.7	14
35	Brain [18F]FDDNP Binding and Glucose Metabolism in Advanced Elderly Healthy Subjects and Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2013, 36, 311-320.	2.6	20
36	Delivery of dopamine transporter tracer (PE2I) through blood brain barrier with ultrasound and microbubbles. , 2012, , .		0

3

JOHNNY VERCOUILLIE

#	Article	IF	CITATIONS
37	Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nuclear Medicine and Biology, 2012, 39, 570-578.	0.6	115
38	Développement de radiotraceurs pour l'imagerie moléculaire du microenvironnement matriciel tumoral (HIMIMT). Irbm, 2012, 33, 86-91.	5.6	1
39	Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 621-631.	6.4	208
40	Imaging of the Striatal and Extrastriatal Dopamine Transporter with ¹⁸ F-LBT-999: Quantification, Biodistribution, and Radiation Dosimetry in Nonhuman Primates. Journal of Nuclear Medicine, 2011, 52, 1313-1321.	5.0	19
41	Automated production of [¹⁸ F]FDDNP using a TRACERIab MX _{FDG} . Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 208-212.	1.0	3
42	Quantification of [18F]LBT-999 binding to the dopamine transporter in the rhesus monkey brain with the HRRT system. NeuroImage, 2010, 52, S118-S119.	4.2	0
43	Neuroimaging of the vesicular acetylcholine transporter by a novel 4-[18F]fluoro-benzoyl derivative of 7-hydroxy-6-(4-phenyl-piperidin-1-yl)-octahydro-benzo[1,4]oxazines. Nuclear Medicine and Biology, 2009, 36, 17-27.	0.6	27
44	Synthesis and in vitro evaluation of new diphenyl ether derivatives as serotonin transporter ligands. Science in China Series B: Chemistry, 2008, 51, 457-463.	0.8	0
45	Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging. Bioorganic and Medicinal Chemistry, 2008, 16, 9050-9055.	3.0	7
46	Avancée de l'imagerie moléculaire dans la maladie d'Alzheimer. Medecine Nucleaire, 2007, 31, 486-4	89.2	0
47	New fluoro-diphenylchalcogen derivatives to explore the serotonin transporter by PET. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4991-4995.	2.2	4
48	Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1297-1300.	2.2	12
49	Synthesis of 1-Tetralone Derivatives Using a Stille Cross Coupling/Friedel Crafts Acylation Sequence ChemInform, 2005, 36, no.	0.0	0
50	[11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse, 2005, 58, 173-183.	1.2	56
51	ADAM is an effective tool for in vivo study of serotonergic function: Validation in rat models. Synapse, 2004, 52, 136-142.	1.2	11
52	Synthesis of 1â€Tetralone Derivatives Using a Stille Cross Coupling/Friedel Crafts Acylation Sequence. Synthetic Communications, 2004, 34, 3751-3762.	2.1	6
53	Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 81-87.	2.5	49
54	Substituted Diphenyl Sulfides as Selective Serotonin Transporter Ligands:  Synthesis and In Vitro Evaluation. Journal of Medicinal Chemistry, 2002, 45, 1253-1258.	6.4	33

#	Article	IF	CITATIONS
55	Synthesis of Tropane and Nortropane Analogues with Phenyl Substitutions as Serotonin Transporter Ligands. Bioorganic and Medicinal Chemistry, 2001, 9, 1849-1855.	3.0	12
56	Precursor synthesis and radiolabelling of [11C]ADAM: a potential radioligand for the serotonin transporter exploration by PET. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, 113-120.	1.0	27
57	Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, 1013-1023.	1.0	61
58	Synthesis of [11C]2?-carbomethoxy-3?-(3?-iodo-4?-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 1033-1046.	1.0	1